[Pharmacological investigation of bezafibrate, a hypolipidemic agent (1). Effects of bezafibrate on normal and experimental hyperlipidemia in rats].
The hypolipidemic effects of bezafibrate were examined in normal rats and an experimentally induced hyperlipidemic model of rats. Oral administration of bezafibrate at 1 mg/kg/day or more to normal rats for 7 days significantly decreased serum triglyceride (TG) and at 3 mg/kg/day or more for 7 days caused significant reduction of serum total cholesterol (TC). A single oral dose of 100 mg/kg of bezafibrate significantly inhibited the increase of serum TC and TG in hyperlipidemic rats induced by Triton WR-1339. When normal rats were given 75% fructose solution for 7 days, serum TG increased in concentration about four times. Oral administration of bezafibrate for 7 days at 1 mg/kg/day or more inhibited the increase of serum TG in this model. Serum TC increased in concentration about twice in 1% cholesterol diet-fed rats for 8 weeks. Oral administration of bezafibrate at 30 mg/kg/day or more inhibited the increase of serum TC. These results suggest that bezafibrate is effective in the treatment of hyperlipidemia.
Kusama
H
H
Central Research Laboratories, Kissei Pharmaceutical Co., Ltd., Matsumoto, Japan.
Nishiyama
M
M
Ikeda
S
S
D000284:Administration, Oral; D000818:Animals; D001629:Bezafibrate / Q000494:pharmacology* / Q000627:therapeutic use; D002791:Cholesterol, Dietary; D003864:Depression, Chemical; D005632:Fructose; D006949:Hyperlipidemias / Q000188:drug therapy*; D008297:Male; D011092:Polyethylene Glycols; D051381:Rats; D014280:Triglycerides / Q000097:blood
D002791:Cholesterol, Dietary; D014280:Triglycerides; D005632:Fructose; D011092:Polyethylene Glycols; C016811:tyloxapol; D001629:Bezafibrate